Rotavirus intestinal infection induces an oral mucosa cytokine response

PLoS One. 2018 Apr 5;13(4):e0195314. doi: 10.1371/journal.pone.0195314. eCollection 2018.

Abstract

Introduction: Salivary glands are known immune effector sites and considered to be part of the whole mucosal immune system. The aim of the present study was to assess the salivary immune response to rotavirus (RV) infection through the analysis of the cytokine immune profile in saliva.

Material and methods: A prospective comparative study of serial saliva samples from 27 RV-infected patients (sampled upon admission to the hospital during acute phase and at convalescence-i.e. at least three months after recovery) and 36 healthy controls was performed. Concentrations of 11 salivary cytokines (IFN-γ, IFN-α2, IL-1β, IL-6, IL-8, IL-10, IL-15, IL12p70, TNF-α, IFN-λ1, IL-22) were determined. Cytokine levels were compared between healthy controls acute infection and convalescence. The correlation between clinical data and salivary cytokine profile in infected children was assessed.

Results: The salivary cytokine profile changes significantly in response to acute RV infection. In RV-infected patients, IL-22 levels were increased in the acute phase with respect to convalescence (P-value < 0.001). Comparisons between infected and control group showed significant differences in salivary IFN-α2, IL-1β, IL-6, IL-8, IL-10 and IL-22. Although acute-phase levels of IL-12, IL-10, IL-6 and IFN-γ showed nominal association with Vesikari's severity, this trend did not reach statistical significance after multiple test adjustment.

Conclusions: RV infection induces a host salivary immune response, indicating that immune mucosal response to RV infection is not confined to the intestinal mucosa. Our data point to a whole mucosal implication in the RV infection as a result of the integrative mucosal immune response, and suggest the salivary gland as effector site for RV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Cytokines / analysis
  • Female
  • Humans
  • Immunity, Mucosal / immunology*
  • Immunity, Mucosal / physiology
  • Infant
  • Infant, Newborn
  • Interleukin-22
  • Interleukins / analysis
  • Intestinal Diseases
  • Intestinal Mucosa / chemistry
  • Intestines / chemistry
  • Male
  • Mouth Mucosa / chemistry
  • Prospective Studies
  • Rotavirus / pathogenicity
  • Rotavirus Infections / immunology*
  • Rotavirus Infections / virology
  • Saliva / chemistry
  • Salivary Glands / physiology*
  • Salivary Glands / virology

Substances

  • Cytokines
  • Interleukins

Grants and funding

This study received support from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud): project GePEM ISCIII/PI16/01478/Cofinanciado FEDER (A.S.) and project ReSVinext ISCIII/PI16/01569/Cofinanciado FEDER (F.M.T.); Consellería de Sanidade, Xunta de Galicia (RHI07/2-intensificación de la actividad investigadora, PS09749 and 10PXIB918184PR), Instituto de Salud Carlos III (Intensificación de la actividad investigadora 2007–2012, PI16/01569), Fondo de Investigación Sanitaria (FIS; PI070069/PI1000540) del Plan Nacional de I + D + I and ‘fondos FEDER’ (F.M.T.), and 2016-PG071 Consolidación e Estructuración REDES 2016GI-1344 (from Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia) G3VIP (Grupo Gallego de Genética Vacunas Infecciones y Pediatría, ED341D R2016/021) (A.S. and F.M.T) and funding from Merck Sharp and Dohme. Funding sources had no involvement in the design of the study, collection, analysis and interpretation of data, and in writing the manuscript. There was no additional external funding received for this study.